The PHG Foundation has submitted evidence to the House of Lords Science and Technology Committee's inquiry into Life Sciences and the Industrial Strategy.
In our response we note the importance of a vibrant UK Life Sciences sector to underpin better health and wealth for the population and welcome recognition that these two aims are not incompatible. To maximise the benefits to UK citizens,we argue the Industrial Strategy should aim to realise the value of the NHS as a test bed for (and potential source of) useful innovations, and help deliver these to NHS professionals and patients promptly, subject to proportionate regulation and careful financial and clinical appraisal.
Brexit poses serious threats to the UK’s current global pre-eminence in the Life Sciences and care must be taken to mitigate these threats, including steps to ensure appropriate implementation of the EU General Data Protection Regulation and In Vitro Diagnostic Devices Regulation and to maintain close working relations with the European Medicines Agency.
Read the full response here